Additionally, where reduced expression is observed in cancers, for example TRIM33, this could potentially be utilised as a biomarker for predicting prognosis or cancer stage, or to stratify patients who may respond to DNA damaging agents or BETi. Here, TRIM33 is linked to cancer.